Abbie Celniker, Ph.D.
Abbie Celniker joined Third Rock in 2016 bringing 30 years of experience in R&D and senior leadership roles. Abbie focuses on the formation, development and strategy of our portfolio companies and has assumed active leadership roles in the following:
- Board member of Cedilla Therapeutics
- Chairman of the board and interim chief executive officer of Rheos Medicines
- Board member and interim chief executive officer of Goldfinch Bio
- Former president and chief executive officer of Eleven Biotherapeutics
Prior to joining the firm, she served as president and CEO of Eleven Biotherapeutics since 2011. Previously, Abbie was the president and CEO of Taligen Therapeutics from 2008 to 2011, when Taligen Therapeutics was acquired by Alexion Pharmaceuticals; following the acquisition, she served as Alexion’s executive vice president, translational medicine. She has served as the global head of biologics of Novartis AG, the senior vice president of R&D strategy and operations of Millennium Pharmaceuticals (now Takeda) and the vice president of protein technologies of the Wyeth Research facilities. Abbie is a member of the MassBio board of directors, a member of the board of ImaginAb, where she was previously the chair, and a member of the scientific advisory board for Adimab. She is also a member of the board of directors of the nonprofit Unitio and T1D. She has a B.A. in biology from the University of California, San Diego, and a Ph.D. in molecular biology from the University of Arizona.
Abbie loves doing jigsaw puzzles, but never looks at the picture on the box, and she once completed a 1000-piece puzzle that was solid white.